Drugs / KRX-0502
KRX-0502
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | AURYXIA | — | 2017-11-06 | fda.gov ↗ |
| Approved | US (FDA) | AURYXIA | — | 2014-09-05 | fda.gov ↗ |
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04299633 | Jun → Aug 2020 | — | Akebia Therapeutics | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02128074 | Apr → Nov 2014 | anemia due to chronic disorder | Keryx Biopharmaceuticals | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT03236246 | Aug 2017 → Aug 2019 | chronic kidney disease, iron deficiency anemia | Keryx Biopharmaceuticals | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
All press releases naming this drug 6 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KRX-0502 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03236246 ↗ |
| Known as | Auryxia | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04299633 ↗ |
| Known as | Ferric citrate coordination complex | ChEMBL registry synonym — accepted as the source's own label CHEMBL3991241 ↗ |
| Known as | Fexeric | ChEMBL registry synonym — accepted as the source's own label CHEMBL3991241 ↗ |
| Modality | Small molecule | — CHEMBL3991241 ↗ |
| Route | Oral | “single oral dose of Auryxia® (2 grams)” NCT04299633 ↗ |